Recognition

2017 European Mediscience Awards – Breakthrough of the Year, CEO of the Year, and Company of the Year Shortlists
In May 2017, HMP parent company Chi-Med was shortlisted in three categories: Breakthrough of the Year, Company of the Year, and CEO of the Year. Now in its 16th year, The European Mediscience Awards is the largest annual gathering of healthcare, biotech and life science companies in Europe to celebrate their achievements and recognise success. It is attended by over 500 companies and their corporate advisers, analysts, fund managers, commentators and peers. The ceremony takes place in London.

The Breakthrough of the Year shortlist highlights organisations that achieved the most significant breakthroughs – new discoveries, departures or breakthroughs in technology, a significant positive change in financial position, or otherwise – which has added significantly to their fortunes. The Chief Executive of the Year shortlist is for individuals who demonstrated exceptional leadership qualities; created shareholder value through drive, vision and flair in taking their business forward; and recognised the importance of developing a management team and workforce in supporting corporate success. The Company of the Year shortlist highlights well managed, soundly financed growth businesses with well defined strategies to deliver their key financial, ethical and social ambitions.

2016 Scrip Awards – Best Company in an Emerging Market Shortlist
In September 2016, the global analysis consultancy Pharma Intelligence announced the shortlist for the 12th Annual Scrip Awards. A panel of 15 respected judges reviewed all the entries to produce a shortlist that displays the wealth of innovation, dedication and hard work that the pharmaceutical and biotech industries have demonstrated over the past year. The full range of industry activities from big pharma, biotech companies and CROs are represented: from novel deals, to new drug launches and finding technological breakthroughs in clinical trials. Once again HMP was present on the shortlist for Best Company in an Emerging Market.

2012 BayHelix-Elsevier Alliance of the Year Award
In September 2012, Elsevier Business Intelligence and the BayHelix Group announced that they awarded prizes to celebrate innovation in China, during an awards ceremony luncheon at the PharmAsia Summit in Shanghai.  Awards recipients were selected from a list of nominees submitted by members of the China and global pharmaceutical community. The Alliance of the Year award recognizes a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.

HMP and AstraZeneca received the award for completing a global licensing, co-development, and commercialization agreement for savolitinib. This partnership represented the first time a major pharmaceutical company had directly licensed a novel clinical ready stage molecule from a biotech company in China, with plans to develop and commercialize it globally, with record setting initial cash payment of US$20 million and further milestone payments of US$120 million.”

Elsevier Business Intelligence

SCRIP Intelligence Award shortlist for Licensing Deal of the Year 2012
In September 2012 SCRIP Intelligence, the leading news, data and intelligence service for the global pharmaceutical industry, announced the shortlist for its internationally renowned annual awards ceremony, the SCRIP Awards 2012. The SCRIP Awards recognize the best companies by identifying those with growth in areas outside of traditional borders in the pharmaceutical and biotechnology industries.   HMP and AstraZeneca’s collaboration on Volitinib was one of six candidates that were carefully selected by a panel of industry judges based on innovation, dedication and impact within the industries.

The Wall Street Journal Asia’s Asian Innovation Awards 2011
In August 2011, HMP was selected as one of the 12 finalists in The Wall Street Journal’s highly prestigious Asian Innovation Awards presented by The Wall Street Journal Asia for its novel drug HMPL-004.  The Awards recognize innovations that break with conventional processes in creative ways. An annual contest, the Asian Innovation Awards seeks to find the next big innovative idea in Asia by selecting from entries regarding breakthroughs in all facets of society.  Finalists were selected from a pool of nearly 260 entries from 18 countries and territories throughout Asia based on three basic factors: degree of innovation, quality of execution, and potential impact on quality of life or productivity.

Wall Street Journal Asian Innovation Awards 2011

Windhover Top 10 Autoimmune Projects to Watch
HMP’s lead drug candidate for Inflammatory Bowel Disease (IBD), HMPL-004, was been chosen by an independent committee from Windhover Information, Inc. and Healogix, LLC as one of the Top 10 Inflammatory/Autoimmune Projects to Watch. This represents a significant industry honor.  The selection criteria included each project’s large unmet market need, the strength of the company and the science, the diversity of current and future indications, and the opportunities for multi-level partnering.
2010 Deloitte Fast 50 China Award
In October 2010 HMP was a winner of Deloitte Touche Tohmatsu’s ranking of top 50 fast-growing technology companies in China.  The Deloitte Technology Fast 50 China program is a yearly ranking of strong growth technology companies by Deloitte, the business advisory firm.  This 2010 program is the 6th anniversary of the highly reputable industry platform, with significant credibility as a benchmark for identifying strong performing technology companies.
Deloitte Technology Fast50
2009 Scrip Awards
The 5th Annual Scrip Awards announced Hutchison MediPharma as a shortlist candidate for the Scrip award in “Best Company in an Emerging Market,” where Scrip seeks to applaud the growth of R&D-based pharmaceutical industries in areas outside of its traditional borders. Other companies shortlisted under this category are Bio Sidus, Cipla, Hikma Pharmaceuticals and Laboratorios Limont.  With a record number of entries this year, Hutchison MediPharma is honored to be a candidate for such a prestigious award.
2009 China’ s Most Innovative Enterprise
China’ s First Innovation Day for Domestic Enterprises and the 9th Annual Innovation Forum of China were successfully held on June 6th in the Great Hall of the People, Beijing.  HMP was awarded “2009 China’ s Most Innovative Enterprise”.  The CEO of HMP was awarded “2009 China’s Outstanding Entrepreneur.” As a leading domestic company in the drug R&D industry, HMP is devoted to pursuing innovation and to bringing innovative drugs to the global market. This award demonstrates the progress of China’ s new drug R&D industry and recognizes HMP’s achievements.
2008 Red Herring Asia 100 Winner
Red Herring is a global media company foucused on uniting the world’ s best high technology innovators, venture investors and business decision makers.  Red Herring selected the 100 “Most Promising” Asian Companies Driving the Future of Technology. HMP was honored to be recognized as a key technology leader in Asia.

The International Award in the 73rd Annual Conference of the American College of Gastroenterology
The American College of Gastroenterology (ACG) is a world renowned scientific association. The College promotes the highest standards in medical education and is guided by its commitment to meeting the needs of clinical gastroenterology practitioners. More than 10,000 physicians from 75 countries are members of the ACG.

HMP received the 2008 International Award from the American College of Gastroenterology for its presentation entitled “Herbal Extract HMPL-004 in Active Ulcerative Colitis: A Randomized Comparison with Sustained Release Mesalamine.”

HMP named 2008 Pudong New Area Enterprise R&D Center
The title is in recognition of HMP’s strong R&D capability by the local government and underscores HMP’s drive towards new drug research and development.
HMP Shortlisted for Scrip Awards 2007
Scrip is a leading global magazine in the pharmaceutical industry. The Scrip Awards recognize the best companies in the pharmaceutical and biotechnological industry.